Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 101–200 of 1,006
Whiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 273
Self-citationA novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 271
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma
Govindarajan, B., Sligh, J. E., Vincent, B. J., Li, M., Canter, J. A., Nickoloff, B. J., Rodenburg, R. J., Smeitink, J. A., Oberley, L., Zhang, Y., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30102 · Cited by 270
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 262
Integrative Genome Comparison of Primary and Metastatic Melanomas
Kabbarah, O., Nogueira, C., Feng, B., Nazarian, R. M., Bosenberg, M., Wu, M., Scott, K. L., Kwong, L. N., Xiao, Y., Cordon-Cardo, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010770 · Cited by 261
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants
Hocker, T., & Tsao, H. (2007) · Human Mutation · doi:10.1002/humu.20481 · Cited by 257
Si, L., Kong, Y., Xu, X., Flaherty, K. T., Sheng, X., Cui, C., Chi, Z., Li, S., Mao, L., & Guo, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.056 · Cited by 255
TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
Griewank, K. G., Murali, R., Puig-Butille, J. A., Schilling, B., Livingstone, E., Potrony, M., Carrera, C., Schimming, T., Möller, I., Schwamborn, M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju246 · Cited by 254
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 252
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Kong, Y., Si, L., Zhu, Y., Xu, X., Corless, C. L., Flaherty, K. T., Li, L., Li, H., Sheng, X., Cui, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2346 · Cited by 251
“%) and Non-CSD (3.2”
InfluentialFecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Melanocytic nevi and melanoma: unraveling a complex relationship
Damsky, W. E., & Bosenberg, M. (2017) · Oncogene · doi:10.1038/onc.2017.189 · Cited by 248
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C., Dobrovic, A., & McArthur, G. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00873.x · Cited by 246
Antonescu, C. R., Busam, K. J., Francone, T. D., Wong, G. C., Guo, T., Agaram, N. P., Besmer, P., Jungbluth, A., Gimbel, M., Chen, C., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22681 · Cited by 245
Self-citationImmunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambiase, A., de Vincentiis, M., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 244
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Ellerhorst, J. A., Greene, V. R., Ekmekcioglu, S., Warneke, C. L., Johnson, M. M., Cooke, C. P., Wang, L.-E., Prieto, V. G., Gershenwald, J. E., Wei, Q., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2276 · Cited by 243
Genome-wide association study identifies three new melanoma susceptibility loci
Barrett, J. H., Iles, M. M., Harland, M., Taylor, J. C., Aitken, J. F., Andresen, P. A., Akslen, L. A., Armstrong, B. K., Avril, M.-F., Azizi, E., et al. (2011) · Nature Genetics · doi:10.1038/ng.959 · Cited by 240
Melanocytes and Their Diseases
Yamaguchi, Y., & Hearing, V. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017046 · Cited by 238
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 238
Stark, M., & Hayward, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4152 · Cited by 237
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta, S., Egyházi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C., & Lui, W.-O. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.63 · Cited by 237
Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review
Lauper, J. M., Krause, A., Vaughan, T. L., & Monnat, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059709 · Cited by 236
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Chong, K., Peng, L., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234
Self-citationGarbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.013 · Cited by 229
Furney, S. J., Turajlic, S., Stamp, G., Nohadani, M., Carlisle, A., Thomas, J. M., Hayes, A., Strauss, D., Gore, M., van den Oord, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4204 · Cited by 229
Søndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J. G., Kehoe, S. M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-39 · Cited by 228
“Discussion The BRAFV600E mutation is one of the most common kinase domain mutations in human cancer with a particularly high incidence in malignant melanoma [3,7].”
BackgroundGriewank, K. G., Westekemper, H., Murali, R., Mach, M., Schilling, B., Wiesner, T., Schimming, T., Livingstone, E., Sucker, A., Grabellus, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0163 · Cited by 226
Deep Learning-Based System for Automatic Melanoma Detection
Adegun, A. A., & Viriri, S. (2020) · IEEE Access · doi:10.1109/access.2019.2962812 · Cited by 225
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 222
Diagnostic and prognostic biomarkers in melanoma.
Weinstein, D. M., Leininger, J., Hamby, C. V., & Safai, B. (2014) · PubMed · Cited by 222
Overall survival and PD‐L1 expression in metastasized malignant melanoma
Gadiot, J., Hooijkaas, A. I., Kaiser, A. D. M., van Tinteren, H., van Boven, H., & Blank, C. (2011) · Cancer · doi:10.1002/cncr.25747 · Cited by 221
Molecular Markers and Targets in Melanoma
Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., & Alos, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 219
Therapy for metastatic melanoma: the past, present, and future
Finn, L., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 218
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Rabbie, R., Ferguson, P., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2019) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 217
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 216
The mutational landscape of mucosal melanoma
Nassar, K. W., & Tan, A. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.013 · Cited by 213
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 212
Bauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00837.x · Cited by 211
“, 2003), resulting in genetically distinct subgroups of melanoma (Curtin et al., 2005).”
BackgroundMethodSelf-citationAnatomic Site, Sun Exposure, and Risk of Cutaneous Melanoma
Whiteman, D. C., Stickley, M., Watt, P., Hughes, M. C., Davis, M. B., & Green, A. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1325 · Cited by 210
Cancer stem cells and human malignant melanoma
Schatton, T., & Frank, M. H. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00427.x · Cited by 210
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma
Massoumi, R., Kuphal, S., Hellerbrand, C., Haas, B., Wild, P., Spruss, T., Pfeifer, A., Fässler, R., & Bosserhoff, A. K. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082044 · Cited by 209
The genetic evolution of metastatic uveal melanoma
Shain, A. H., Bagger, M. M., Yu, R., Chang, D., Liu, S., Vemula, S., Weier, J. F., Wadt, K., Heegaard, S., Bastian, B. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0440-9 · Cited by 209
Self-citationLovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D., Hicks, D. J., Hucks, D., Berry, E., Terry, C., Duke, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035309 · Cited by 206
Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
Morton, L. M., Curtis, R. E., Linet, M. S., Bluhm, E. C., Tucker, M. A., Caporaso, N., Ries, L. A. G., & Fraumeni, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.1112 · Cited by 205
The Regulation of miRNA-211 Expression and Its Role in Melanoma Cell Invasiveness
Mazar, J., DeYoung, K., Khaitan, D., Meister, E., Almodovar, A., Goydos, J., Ray, A., & Perera, R. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013779 · Cited by 204
Zhuang, D., Mannava, S., Grachtchouk, V, Tang, W.-H., Patil, S., Wawrzyniak, J. A., Berman, A. E., Giordano, T. J., Prochownik, E. V., Soengas, M. S., et al. (2008) · Oncogene · doi:10.1038/onc.2008.258 · Cited by 203
Wiesner, T., Kutzner, H., Cerroni, L., Mihm, M. C., Busam, K. J., & Murali, R. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.007 · Cited by 202
Self-citationKuk, D., Shoushtari, A. N., Barker, C. A., Panageas, K. S., Munhoz, R. R., Momtaz, P., Ariyan, C. E., Brady, M. S., Coit, D. G., Bogatch, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0522 · Cited by 201
Lian, B., Si, L., Cui, C., Chi, Z., Sheng, X., Mao, L., Li, S., Kong, Y., Tang, B., & Guo, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0739 · Cited by 200
Norval, M., Cullen, A. P., de Gruijl, F. R., Longstreth, J., Takizawa, Y., Lucas, R. M., Noonan, F. P., & van der Leun, J. C. (2007) · Photochemical & Photobiological Sciences · doi:10.1039/b700018a · Cited by 199
How to make a melanoma: what do we know of the primary clonal events?
Bennett, D. C. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00433.x · Cited by 198
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 196
Nathanson, K. L., Martin, A.-M., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J. R., Falchook, G. S., Arkenau, H.-T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 196
KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites
Omholt, K., Grafström, E., Kanter-Lewensohn, L., Hansson, J., & Ragnarsson-Olding, B. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2917 · Cited by 194
Fan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C.-C. R., & Hornyak, T. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0511 · Cited by 193
Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
Thomas, N. E., Edmiston, S. N., Alexander, A., Millikan, R. C., Groben, P. A., Hao, H., Tolbert, D., Berwick, M., Busam, K., Begg, C. B., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1038 · Cited by 192
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., Fargnoli, M. C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.014 · Cited by 192
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 195
Hocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
Joosse, A., Collette, S., Suciu, S., Nijsten, T., Lejeune, F., Kleeberg, U. R., Coebergh, J. W. W., Eggermont, A. M. M., & de Vries, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0584 · Cited by 189
Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
Bertolotto, C. (2013) · Scientifica · doi:10.1155/2013/635203 · Cited by 197
Liu, W., Kelly, J. W., Trivett, M., Murray, W. K., Dowling, J. P., Wolfe, R., Mason, G., Magee, J., Angel, C., Dobrovic, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700632 · Cited by 188
Yamaura, M., Mitsushita, J., Furuta, S., Kiniwa, Y., Ashida, A., Goto, Y., Shang, W. H., Kubodera, M., Kato, M., Takata, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3745 · Cited by 187
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C. M., Van Gulick, R., Kazakoff, S. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18988-3 · Cited by 186
The Genomic Landscape of Childhood and Adolescent Melanoma
Lu, C., Zhang, J., Nagahawatte, P., Easton, J., Lee, S., Liu, Z., Ding, L., Wyczalkowski, M. A., Valentine, M., Navid, F., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.425 · Cited by 186
Mucosal melanoma of the head and neck
Ascierto, P. A., Accorona, R., Botti, G., Farina, D., Fossati, P., Gatta, G., Gogas, H., Lombardi, D., Maroldi, R., Nicolai, P., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.019 · Cited by 185
Targeted Genomic Profiling of Acral Melanoma
Yeh, I., Jorgenson, E., Shen, L., Xu, M., North, J. P., Shain, A. H., Reuss, D., Wu, H., Robinson, W. A., Olshen, A., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz005 · Cited by 185
Self-citationSchreuer, M., Jansen, Y., Planken, S., Chevolet, I., Seremet, T., Kruse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 184
Balch, C. M., Thompson, J. F., Gershenwald, J. E., Soong, S.-J., Ding, S., McMasters, K. M., Coit, D. G., Eggermont, A. M. M., Gimotty, P. A., Johnson, T. M., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3464-x · Cited by 183
Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Heppt, M. V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., Kirchner, T., Jung, A., Gesierich, A., Ruzicka, T., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3529-5 · Cited by 182
Comparative Aspects of Canine Melanoma
Nishiya, A. T., Massoco, C. D. O., Felizzola, C. R., Perlmann, E., Batschinski, K., Tedardi, M. V., Garcia, J. S., Mendonça, P., Teixeira, T. F., & Dagli, M. Z. (2016) · Veterinary Sciences · doi:10.3390/vetsci3010007 · Cited by 181
Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison
Prouteau, A., & André, C. (2019) · Genes · doi:10.3390/genes10070501 · Cited by 181
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 180
Melanoma Epidemiology and Sun Exposure
Raimondi, S., Suppa, M., & Gandini, S. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3491 · Cited by 179
The genetics of uveal melanoma: an emerging framework for targeted therapy
Harbour, J. W. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00979.x · Cited by 178
Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0459 · Cited by 178
McArthur, G. A., Puzanov, I., Amaravadi, R., Ribas, A., Chapman, P., Kim, K. B., Sosman, J. A., Lee, R. J., Nolop, K., Flaherty, K. T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1938 · Cited by 178
Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 177
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 177
Histopathologic classification and prognostic factors of melanoma: a 2021 update
Bobos, M. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.21.06958-3 · Cited by 178
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
Satzger, I., Schaefer, T., Küttler, U., Broecker, V., Völker, B., Ostertag, H., Kapp, A., & Gutzmer, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604791 · Cited by 177
Zell, J. A., Cinar, P., Mobasher, M., Ziogas, A., Meyskens, F. L., & Anton-Culver, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3604 · Cited by 176
“Recently, gene alterations were shown to vary with melanoma site and also with sun exposure levels.(38) Skin melanomas without signs of chronic sun-induced damage (CSD) frequently harbor mutations in BRAF or NRAS.”
BackgroundInfluentialWNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T., Rizos, H., Long, G. V., von Euw, E. M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 176
Hintzsche, J. D., Gorden, N. T., Amato, C. M., Kim, J., Wuensch, K. E., Robinson, S. E., Applegate, A. J., Couts, K. L., Medina, T. M., Wells, K. R., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000345 · Cited by 176
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175
“applicability of BRAF inhibitor–based therapy is limited.(8) c-Kit mutations occur in approximately 15% of mucosal melanomas but are associated with a response rate of 35% to c-Kit inhibitors.”
BackgroundModelling cancer in human skin tissue
Khavari, P. A. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1838 · Cited by 176
Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Johnson, D. B., Lovly, C. M., Flavin, M., Panageas, K. S., Ayers, G. D., Zhao, Z., Iams, W. T., Colgan, M., DeNoble, S., Terry, C. R., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0207 · Cited by 174
The genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
Mao, L., Qi, Z., Zhang, L., Guo, J., & Si, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680407 · Cited by 172
BRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma
Muthusamy, V., Duraisamy, S., Bradbury, C. M., Hobbs, C., Curley, D. P., Nelson, B., & Bosenberg, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1274 · Cited by 172
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
Zebary, A., Jangard, M., Omholt, K., Ragnarsson-Olding, B., & Hansson, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.373 · Cited by 172
Genetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171
“Notably, loss of chromosome 15q material in melanoma is not a very rare event (37, 38).”
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.